secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0001641172-25-019892
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell closes $15M public offering of 12M units at $1.25/unit
---------------------------------------------------------------

- Gross proceeds of $15M before fees; 12,000,000 units sold at $1.25 per unit.
- Each unit comprises one common share (or pre-funded warrant at $0.001) and one warrant exercisable at $1.50 for five years.
- ThinkEquity acted as sole placement agent; cash fee of 7.5% of gross proceeds.
- Net proceeds earmarked for working capital, general corporate purposes, and advancement of business objectives.
- Relies on TSX exemption for interlisted issuers; no Canadian prospectus filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225019892/0001641172-25-019892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225019892/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer